Abstract: An embodiment provisions overflow from on-premises cloud workload onto a secure infrastructure provider. The embodiment senses a performance metric of an on-premises cloud. The embodiment deciding, responsive to the sensed performance metric, to scale up, senses a property of an infrastructure provider, responsive to the sensed property, selects the infrastructure provider. The embodiment generates credentials, creates a secure environment, establishes secure communications, and provisions compute hosts in the selected infrastructure provider.

Abstract: Systems and methods for blood flow and perfusion measurement using complex amplitude modulation of MRI pulses are presented. In exemplary embodiments of the disclosed subject matter, inflowing arterial spins can be modulated using a complex modulation function having certain mathematical properties in the frequency domain, such as, for example, a pseudo-random sequence. In exemplary embodiments of the disclosed subject matter the mathematical properties of such complex modulation functions can be used to measure individual transit times by deconvolving them from a series of acquired images. In exemplary embodiments of the disclosed subject matter images can be acquired at the same rapid rate as arterial modulation, and transit time distribution in the imaged tissue can be determined as part of a single integrated acquisition.

Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.

Abstract: The invention provides for methods for producing water-soluble iron oxide nanoparticles comprising encapsulating the nanoparticles in phospholipids micelles. Also provided are methods for conjugating the inventive nanoparticles via functionalized phospholipids to a target molecule, such as an antibody. The invention further provides methods for using the nanoparticle-antibody conjugate of the invention as a contrast agent to image specific cells or proteins in a subject using fluorescent and magnetic imaging techniques.

Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.

Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a recently discovered metabolic pathway. According to the normal functioning of this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3-deoxyglucosone (3DG).

Abstract: Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

Abstract: An arrangement adapted for viewing at least one liquid crystal display includes at least one lens provided in a particular orientation so as to at least partially reduce attenuation of a polarized light emitted by the at least one liquid crystal display. Another arrangement adapted for viewing at least one liquid crystal display includes at least one lens, having an upper portion and a lower portion, the upper portion being provided in a first orientation being arranged so as to at least partially reduce a glare from ambient light, the lower portion being provided in a second orientation being arranged so as to at least partially reduce attenuation of a polarized light emitted by the at least one liquid crystal display.